"Pfizer is committed to pursuing compelling science taking
place outside our laboratories, and the agreement to acquire
Serenex is a splendid example of those efforts.
The Serenex oncology candidate extends Pfizer’s substantial
internal research efforts to develop novel treatments for cancer,
a leading cause of death in the United States and much of the world.”
Martin Mackay, president of Pfizer Global Research and Development.
For more information about Pfizer and its innovative approach to drug
development, please visit:
